SCHEMBL370750

SCHEMBL370750

COc1ccc(Cn2cc3c(n2)C(C)OC(C)(C)c2sc(N)nc2-3)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.35
KCNH2 Q12809 1/20 0.35
AADAT Q8N5Z0 1/20 0.34
POLB P06746 2/20 0.33
ALDH1A1 P00352 2/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
PDE8B O95263 1/20 0.32
FBP1 P09467 1/20 0.32
RXFP1 Q9HBX9 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
NR1I3 Q14994 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 2/20 0.31
KDM4E B2RXH2 2/20 0.31
MYC P01106 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837226 0.82 DRD2 (0.36) DRD2KCNH2AADATPOLBALDH1A1
SCHEMBL369350 0.80 GRM4 (0.34) RXFP1MEN1NPC1RAB9AKMT2A
SCHEMBL368608 0.80 ADORA1 (0.40) DRD2KCNH2AADATPOLBALDH1A1
SCHEMBL369019 0.80 DRD2 (0.37) DRD2KCNH2AADATPOLBALDH1A1
SCHEMBL371000 0.75 KDM4E (0.45) DRD2KCNH2AADATALDH1A1FBP1
SCHEMBL371092 0.73 ADORA1 (0.39) DRD2KCNH2AADATPOLBALDH1A1
SCHEMBL369977 0.72 KDM4E (0.44) DRD2KCNH2AADATALDH1A1FBP1
SCHEMBL6837465 0.72 AADAT (0.39) DRD2KCNH2AADATPOLBALDH1A1
SCHEMBL370449 0.70 MAPT (0.42) DRD2KCNH2AADATALDH1A1FBP1
SCHEMBL15260941 0.70 AADAT (0.42) DRD2KCNH2AADATALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 DRD2 754/4885KCNH2 1260/4885AADAT 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.